Differential blood lipid-lowering effects of alkylsulfonated chitosan of different molecular weights in Syrian hamsters in vivo.
Differential blood lipid-lowering effects of alkylsulfonated chitosan of different molecular weights in Syrian hamsters in vivo.
复制标题
DOI：
10.3892/mmr.2011.705
复制
发表时间：
2011-12
影响因子：
3.4
通讯作者：
Chih-Chung Wu;Shang-Ying Lin;Chi-Tsai Chen;Yueh-Ping Chang;Yun-Shan Huang;C. Lii;Chien‐Chih Yu;S. Hsieh;Jing-Gung Chung
中科院分区：
文献类型：
--
作者：
Chih-Chung Wu;Shang-Ying Lin;Chi-Tsai Chen;Yueh-Ping Chang;Yun-Shan Huang;C. Lii;Chien‐Chih Yu;S. Hsieh;Jing-Gung Chung
本研究探讨了不同分子量的烷基磺化壳聚糖对肠道脂质吸收、血脂谱和循环粘附分子的影响。叙利亚仓鼠饲喂基于 AIN-93G 的高脂饮食 (HFD)，并每周口服 4 次 5 或 10 mg/kg 体重的低聚物 (6 kDa) 壳聚糖 (OC)、低分子量 (70 kDa) 壳聚糖 (LMC) 或高分子量 (200 kDa) 壳聚糖 (HMC)，共 12 次。 几周。接受 2.5 mg/kg BW 洛伐他汀 (LOVA) 的动物作为阳性对照。这些对照动物的血脂谱显示，与 HFD 喂养的对照组相比，所有壳聚糖和 LOVA 均以剂量依赖性方式显着降低总甘油三酯、总胆固醇、低密度脂蛋白 (LDL) 胆固醇和极低密度脂蛋白 (VLDL) 胆固醇水平 (POC>HMC。接受 5 和 10 剂量的仓鼠 mg/kg LMC (P<0.05) 表现出粪便脂肪含量增加。免疫印迹分析显示，与 HFD 喂养的对照相比，所有壳聚糖喂养的动物中酰基辅酶 A：胆固醇酰基转移酶 2 (ACAT-2) 的表达均受到抑制（P<0.05）。这些结果表明，壳聚糖可有效降低血脂含量，其有效性取决于 壳聚糖分子大小的影响。壳聚糖的降血脂作用部分归因于其抑制肠道脂质吸收和肝脏 ACAT-2 表达。
This study investigated the effects of alkylsulfonated chitosan of different molecular weights on intestinal lipid absorption, blood lipid profiles and circulating adhesion molecules. Syrian hamsters were fed an AIN-93G-based high‑fat diet (HFD) and were orally administered 5 or 10 mg/kg BW of oligomer (6 kDa) chitosan (OC), low‑molecular-weight (70 kDa) chitosan (LMC) or high‑molecular-weight (200 kDa) chitosan (HMC) four times per week for 12 weeks. Animals receiving 2.5 mg/kg BW lovastatin (LOVA) served as a positive control. The blood lipid profiles of these control animals revealed that all chitosans and LOVA significantly decreased total triglyceride, total cholesterol, low‑density lipoprotein (LDL)-cholesterol and very‑low‑density lipoprotein (VLDL)-cholesterol levels in a dose‑dependent manner compared to the HFD-fed controls (POC>HMC. Hamsters receiving 5 and 10 mg/kg LMC (P<0.05) exhibited an increase in fecal fat content. Immunoblot assay revealed that acyl‑coenzyme A:cholesterol acyltransferase-2 (ACAT-2) expression was suppressed in all chitosan-fed animals compared to the HFD-fed controls (P<0.05). These results suggest that chitosan effectively decreases blood lipid content, and its effectiveness depends on the molecular size of chitosan. The hypolipidemic effect of chitosan is partly attributed to its suppression of intestinal lipid absorption and hepatic ACAT-2 expression.